Grifols
- Country
- 🇪🇸Spain
- Ownership
- Subsidiary, Public
- Established
- 1940-01-01
- Employees
- 23.7K
- Market Cap
- $6.8B
- Website
- http://www.grifols.com
- Introduction
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- Conditions
- HypogammaglobulinemiaBacterial InfectionsB-cell Chronic Lymphocytic LeukemiaMultiple MyleomaNon-Hodgkin Lymphoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 386
- Registration Number
- NCT05645107
- Locations
- 🇧🇦
GC2202 Study Site 701, Sarajevo, Bosnia and Herzegovina
🇺🇸GC2202 Decentralized Study Site 114, Morrisville, North Carolina, United States
🇧🇬GC2202 Study Site 211, Sofia, Bulgaria
A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients
- Conditions
- COVID-19Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
- Interventions
- Biological: C19-IG 20%
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 465
- Registration Number
- NCT04847141
- Locations
- 🇪🇸
Hospital Sant Pau i Santa Tecla, Tarragona, Spain
🇪🇸Centro de Salud San Andrés, Madrid, Spain
🇪🇸CAP Manso, Barcelona, Spain
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants with Alpha1-Antitrypsin Deficiency
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- Biological: Liquid Alpha1-Proteinase Inhibitor (Human)
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 16
- Registration Number
- NCT04722887
- Locations
- 🇺🇸
Dignity Health-St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
- Conditions
- Primary Immunodeficiency
- Interventions
- Biological: IGSC 20%
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 33
- Registration Number
- NCT04566692
- Locations
- 🇺🇸
AARA Research Center, Dallas, Texas, United States
🇺🇸Institute for Asthma and Allergy, Chevy Chase, Maryland, United States
🇺🇸Optimed Research LTD, Columbus, Ohio, United States
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency
- Conditions
- Primary Immunodeficiency
- Interventions
- Biological: IVIG-PEGBiological: Gamunex-C
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 33
- Registration Number
- NCT04561115
- Locations
- 🇺🇸
AARA Research Center, Dallas, Texas, United States
🇺🇸Optimed Research, LLC, Columbus, Ohio, United States
🇺🇸Alabama Allergy & Asthma Center, Birmingham, Alabama, United States
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
- Conditions
- COVID-19
- Interventions
- Biological: Liquid Alpha1-Proteinase Inhibitor (Human)Drug: PlaceboDrug: Standard Medical Treatment
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 57
- Registration Number
- NCT04547140
- Locations
- 🇺🇸
Sparrow Hospital, Lansing, Michigan, United States
🇧🇷AngioCor Blumenau, Blumenau, Santa Catarina, Brazil
🇧🇷Universidade Estadual São Paulo - Campus de Botucatu, Botucatu, São Paulo, Brazil
Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
- Conditions
- COVID-19
- Interventions
- Drug: Standard Medical TreatmentBiological: GAMUNEX-C
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2022-10-07
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 100
- Registration Number
- NCT04480424
- Locations
- 🇺🇸
Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
🇺🇸Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Southern California Research Center, Coronado, California, United States
Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency
- Conditions
- Primary Immunodeficiency
- Interventions
- Biological: IGSC 20% daily push versus 2 times per week pumpBiological: IGSC 20% daily push versus once a week pumpBiological: IGSC 20% 150 mg/kgBiological: IGSC 20% daily push versus every 2 weeks pump
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- Grifols Therapeutics LLC
- Registration Number
- NCT03814798
- Locations
- 🇺🇸
The South Bend Clinic LLP, South Bend, Indiana, United States
🇺🇸Oklahoma Institute of Allergy and Asthma Clinical Research, Oklahoma City, Oklahoma, United States
🇺🇸Optimed Research LTD, Columbus, Ohio, United States
Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%
- Conditions
- Acute-On-Chronic Liver Failure
- Interventions
- Biological: SMT + PE-A 5%Other: Standard Medical Treatment
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 275
- Registration Number
- NCT03702920
- Locations
- 🇵🇹
Centro Hospitalar Lisboa Norte, Lisboa, Portugal
🇪🇸Hospital General Gregorio Marañón, Madrid, Spain
🇬🇧Nottingham University Hospital, Nottingham, United Kingdom
Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites
- Conditions
- Decompensated Cirrhosis and Ascites
- Interventions
- Other: Standard medical treatment
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 410
- Registration Number
- NCT03451292
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Missouri Hospital, Columbia, South Carolina, United States
🇺🇸Southern California Research Center, Coronado, California, United States